Fingerstick blood assay maps real-world NAD<sup>+</sup> disparity across gender and age.
Where this comes from
- Record sourced from PubMed, PMID 37641521.
- Also identified by DOI 10.1111/acel.13965 and PMC identifier 10577551.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Nicotinamide adenine dinucleotide (NAD<sup>+</sup> ) level has been associated with various age-related diseases and its pharmacological modulation emerges as a potential approach for aging intervention. But human NAD<sup>+</sup> landscape exhibits large heterogeneity. The lack of rapid, low-cost assays limits the establishment of whole-blood NAD<sup>+</sup> baseline and the development of personalized therapies, especially for those with poor responses towards conventional NAD<sup>+</sup> supplementations. Here, we developed an automated NAD<sup>+</sup> analyzer for the rapid measurement of NAD<sup>+</sup> with 5 μL of capillary blood using recombinant bioluminescent sensor protein and automated optical reader. The minimal invasiveness of the assay allowed a frequent and decentralized mapping of real-world NAD<sup>+</sup> dynamics. We showed that aerobic sport and NMN supplementation increased whole-blood NAD<sup>+</sup> and that male on average has higher NAD<sup>+</sup> than female before the age of 50. We further revealed the long-term stability of human NAD<sup>+</sup> baseline over 100 days and identified major real-world NAD<sup>+</sup> -modulating behaviors.
Medical subject headings
- NAD
- Nicotinamide Mononucleotide